Table 3.
Key data of 3 study participants infected on enrolment and 2 participants who acquired Plasmodium infections during the study period
| Participant | #107 | #124 | #006 |
|---|---|---|---|
| Baseline | |||
| Date 1 | 21/7/16 | 24/8/16 | 20/5/16 |
| Species | Pf | Pv | Not infected |
| K13 | C580Y | Not tested | |
| ExoE415G | E415G | ||
| P14 CNV | Single copy | ||
| Pfmdr1 CNV | Single copy | ||
| Parasites/ml | 22,225 | 1505 | |
| Treatment 1 | ACT + 14 days primaquine (15 mg/day) | ||
| Pre-forest entry | |||
| Date 2 | 7/8/16 | 9/10/16 | 6/6/16 |
| Species | Pf | Not infected | Pf |
| K13 | C580Y | Wild type | |
| ExoE415G | E415G | Insufficient DNA sample for testing | |
| P14 CNV | Multicopies | ||
| Pfmdr1 CNV | Single copy | Single copy | |
| Parasites/ml | 6412 | 663 | |
| Treatment 2 | ACT | ACT | Placebo |
| Forest days | 10 | 5 | 20 |
| Camp | Not known | Campsitea | Camp 8 Tram 7 |
| 15 days after return from forest | |||
| Date 3 | 6/9/16 | 4/11/16 | 12/7/16 |
| Species | Not infected | Pf | Pf |
| K13 | C580Y | C580Y | |
| ExoE415G | E415G | E415G | |
| P14 CNV | Multicopies | Multicopies | |
| Pfmdr1 CNV | Single copy | Single copy | |
| Parasites/ml | 5142 | 111,500 | |
aCamp: “campsite” refers to an overnight campsite while the rangers are moving through the forest